News & Events
Disc Medicine Reports Second Quarter 2023 Financial Results and Provides Business Update
Presented positive initial safety and efficacy data from the BEACON trial at the European Hematology Association (EHA) Congress in June 2023; data from all patients in BEACON to be presented year-end 2023 Initiated a phase 1/2 study of bitopertin in patients with Diamond-Blackfan Anemia who have
More News
Disc Medicine Presents Positive Data from SAD Cohorts of a Phase 1b Trial in Patients with Chronic Kidney Disease (CKD) and Anemia at the 2024 American Society of Nephrology (ASN) Kidney Week
WATERTOWN, Mass., Oct. 25, 2024 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and...
read more
Disc Medicine Appoints Seasoned Industry Executive Rahul Kaushik, Ph.D. as Chief Technical Officer
Dr. Rahul Rajan Kaushik is an accomplished technical operations leader with over two decades of expertise in Chemistry, Manufacturing and Controls (CMC)...
read more
Disc Medicine Announces Presentation of New Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2024 American Society of Nephrology (ASN) Kidney Week
WATERTOWN, Mass., Oct. 11, 2024 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and...
read more